JP6598786B2 - ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 - Google Patents

ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 Download PDF

Info

Publication number
JP6598786B2
JP6598786B2 JP2016546998A JP2016546998A JP6598786B2 JP 6598786 B2 JP6598786 B2 JP 6598786B2 JP 2016546998 A JP2016546998 A JP 2016546998A JP 2016546998 A JP2016546998 A JP 2016546998A JP 6598786 B2 JP6598786 B2 JP 6598786B2
Authority
JP
Japan
Prior art keywords
edem
bdm
membrane
vesicle
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016546998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502997A (ja
JP2017502997A5 (https=
Inventor
ベーア ジョエル デ
Original Assignee
アンヤリウム バイオサイエンシーズ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンヤリウム バイオサイエンシーズ アーゲー filed Critical アンヤリウム バイオサイエンシーズ アーゲー
Publication of JP2017502997A publication Critical patent/JP2017502997A/ja
Publication of JP2017502997A5 publication Critical patent/JP2017502997A5/ja
Application granted granted Critical
Publication of JP6598786B2 publication Critical patent/JP6598786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
JP2016546998A 2014-01-21 2015-01-20 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 Active JP6598786B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461929559P 2014-01-21 2014-01-21
US61/929,559 2014-01-21
PCT/IB2015/050436 WO2015110957A2 (en) 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019113819A Division JP7046872B2 (ja) 2014-01-21 2019-06-19 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Publications (3)

Publication Number Publication Date
JP2017502997A JP2017502997A (ja) 2017-01-26
JP2017502997A5 JP2017502997A5 (https=) 2017-12-21
JP6598786B2 true JP6598786B2 (ja) 2019-10-30

Family

ID=52434912

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016546998A Active JP6598786B2 (ja) 2014-01-21 2015-01-20 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用
JP2019113819A Active JP7046872B2 (ja) 2014-01-21 2019-06-19 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用
JP2022045805A Pending JP2022101548A (ja) 2014-01-21 2022-03-22 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019113819A Active JP7046872B2 (ja) 2014-01-21 2019-06-19 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用
JP2022045805A Pending JP2022101548A (ja) 2014-01-21 2022-03-22 ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用

Country Status (13)

Country Link
US (3) US10561610B2 (https=)
EP (2) EP3096741B1 (https=)
JP (3) JP6598786B2 (https=)
KR (3) KR102541164B1 (https=)
CN (2) CN105934240B (https=)
AU (3) AU2015208837B2 (https=)
CA (1) CA2936514C (https=)
DK (1) DK3096741T3 (https=)
EA (1) EA037503B1 (https=)
ES (1) ES2821758T3 (https=)
MX (2) MX384911B (https=)
WO (1) WO2015110957A2 (https=)
ZA (1) ZA201604831B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
US10272137B2 (en) 2013-06-27 2019-04-30 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
EA037503B1 (ru) 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
US20170035700A1 (en) 2014-04-11 2017-02-09 University Of Louisville Research Foundation, Inc. Coated edible plant-derived microvesicle compositions and methods for using the same
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017136430A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
KR20230074598A (ko) * 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
CN106280533B (zh) * 2016-08-17 2018-03-09 赣南师范大学 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记
EP3292861A1 (en) * 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector
JP2020517750A (ja) * 2017-04-19 2020-06-18 エイピーエイ− アドバンスト・テクノロジーズ・リミテッドＡｐａ− Ａｄｖａｎｃｅｄ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｔｄ． 癌処置のための融合性リポソーム、組成物、キットおよびその使用
CN107084956B (zh) * 2017-05-05 2021-03-23 曲阜师范大学 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法
AU2018266111B2 (en) * 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US12433843B2 (en) 2017-07-28 2025-10-07 National University Of Singapore Biomolecular composites comprising modified cell ghosts
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
JP2020537498A (ja) * 2017-09-11 2020-12-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類細胞へのｃａｓ９の抗体媒介性送達
WO2019066434A1 (ko) * 2017-09-30 2019-04-04 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
KR102008665B1 (ko) * 2017-09-30 2019-08-08 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
US20200330616A1 (en) * 2017-11-13 2020-10-22 POLITECNICO Dl TORINO Biomimetic non-immunogenic nanoassembly for the antitumor therapy
US12036262B2 (en) 2017-11-22 2024-07-16 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
CN108287134B (zh) * 2017-12-28 2020-11-24 南京邮电大学 单颗粒生物探针及其等离子体生物存储器的构建方法
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
JP7551110B2 (ja) 2018-04-06 2024-09-17 ノース カロライナ ステート ユニバーシティ 癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達
AU2019251449A1 (en) 2018-04-09 2020-11-12 Orgenesis Inc. Bioxomes particles, redoxomes, method and composition
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN110437628B (zh) * 2018-05-04 2021-05-04 中国石油化工股份有限公司 一种改性剂母液和道路沥青及其合成方法
AU2019269593A1 (en) * 2018-05-15 2020-11-26 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3813798A1 (en) * 2018-06-28 2021-05-05 AstraZeneca AB Exosome extracellular vesicles and methods of use
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
EP3880832A1 (en) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CN109620969B (zh) * 2019-01-30 2021-02-05 广东药科大学 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法
WO2021010586A1 (ko) * 2019-07-15 2021-01-21 (주)심플스틱 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법
KR20220044816A (ko) * 2019-08-12 2022-04-11 인티그레이티드 나노테라퓨틱스 아이엔씨. 하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
WO2021034582A1 (en) * 2019-08-16 2021-02-25 Children's Medical Center Corporation Large scale production of exosome mimetics and uses thereof
CN112415081A (zh) * 2019-08-23 2021-02-26 四川大学 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法
KR102297995B1 (ko) * 2019-10-24 2021-09-02 포항공과대학교 산학협력단 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
US20230285297A1 (en) * 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
EP3858332A1 (en) 2020-01-31 2021-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bottom-up assembly of synthetic extracellular vesicles
JP7744354B2 (ja) * 2020-02-25 2025-09-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善された方法
US20230143984A1 (en) * 2020-03-20 2023-05-11 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
CN112094809A (zh) * 2020-10-19 2020-12-18 军事科学院军事医学研究院环境医学与作业医学研究所 一种从血清或血浆中提取外泌体的方法
IL307544A (en) 2021-04-08 2023-12-01 Sana Biotechnology Inc Cd8-specific antibody constructs and compositions thereof
US20240218046A1 (en) 2021-04-14 2024-07-04 Anjarium Biosciences Ag Fc-derived polypeptides
CA3214655A1 (en) 2021-04-14 2022-10-20 Joel DE BEER Peptides, nanovesicles, and uses thereof for drug delivery
JP2024515104A (ja) 2021-04-20 2024-04-04 テラパワー， エルエルシー Ａｃ－２２５生成のためのチタニアに基づくジェネレータ
JP2024522149A (ja) * 2021-06-04 2024-06-11 インスティテュート フォー ベーシック サイエンス ナノベシクルリアクター及びその製造方法
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
JPWO2023027082A1 (https=) * 2021-08-23 2023-03-02
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023244084A1 (ko) * 2022-06-17 2023-12-21 주식회사 엠디뮨 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법
CN121038801A (zh) 2022-10-24 2025-11-28 Ags治疗简易股份公司 来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途
EP4665865A1 (en) 2023-02-17 2025-12-24 Anjarium Biosciences AG Methods of making dna molecules and compositions and uses thereof
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma
WO2024249782A2 (en) * 2023-06-02 2024-12-05 The Methodist Hospital Biomimetic proteolipid nanovesicles for delivery of nucleic acids
EP4719632A1 (en) 2023-07-06 2026-04-08 National Resilience, LLC Methods and compositions for purifying particles and macromolecules
KR20250018222A (ko) * 2023-07-26 2025-02-05 차의과학대학교 산학협력단 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물
WO2025100747A1 (ko) * 2023-11-09 2025-05-15 주식회사 엑토좀 줄기세포 유래 엑토-리포좀 융합 나노입자 및 그의 용도
WO2025137252A1 (en) * 2023-12-20 2025-06-26 Cz Biohub Sf, Llc High throughput method for screening lipid nanoparticle efficacy and cytotoxicity
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
WO2025196641A1 (ru) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Гибридные частицы, способ их получения и применение
KR20250150723A (ko) * 2024-04-11 2025-10-21 주식회사 하이셀텍 하이브리드 엑소좀 및 이의 용도
KR20250156281A (ko) * 2024-04-25 2025-11-03 주식회사 보름바이오 고분자 나노입자와 세포막이 하이브리드화된 나노복합체 및 이의 의학적 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
US8455188B2 (en) * 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP3569254B1 (en) 2009-04-17 2022-07-20 Oxford University Innovation Limited Composition for delivery of genetic material
KR100950713B1 (ko) 2009-07-15 2010-03-31 (주)블루앤 음이온 발생기를 구비한 엘이디 램프
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP5149921B2 (ja) * 2010-02-19 2013-02-20 学校法人君が淵学園 癌細胞増殖抑制性ハイブリッド型リポソーム製剤
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
CN103079592B (zh) 2010-07-01 2015-10-21 浦项工科大学校产学协力团 使用来自细胞的微泡治疗和诊断癌症的方法
KR101130137B1 (ko) 2010-07-02 2012-03-28 연세대학교 산학협력단 발광다이오드 모듈
US20120058153A1 (en) 2010-08-20 2012-03-08 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
ES2888231T3 (es) 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
JP2013545727A (ja) 2010-10-21 2013-12-26 メルク・シャープ・アンド・ドーム・コーポレーション オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
EP2635265B1 (en) 2010-11-05 2018-04-04 Sirna Therapeutics, Inc. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
WO2013048734A1 (en) * 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP2013128452A (ja) * 2011-12-21 2013-07-04 Toshiba Corp 定量分析装置、定量分析方法、脂質膜小胞、及び試薬
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
JP2016507543A (ja) 2013-02-07 2016-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 小胞を含む医薬組成物
EA037503B1 (ru) 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
CA3214655A1 (en) 2021-04-14 2022-10-20 Joel DE BEER Peptides, nanovesicles, and uses thereof for drug delivery
US20240218046A1 (en) 2021-04-14 2024-07-04 Anjarium Biosciences Ag Fc-derived polypeptides
AU2022260111A1 (en) 2021-04-20 2023-11-30 Anjarium Biosciences Ag Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法

Also Published As

Publication number Publication date
US20230181467A1 (en) 2023-06-15
WO2015110957A2 (en) 2015-07-30
EP3096741A2 (en) 2016-11-30
AU2015208837A1 (en) 2016-08-11
EP3791863A1 (en) 2021-03-17
US11484500B2 (en) 2022-11-01
CA2936514C (en) 2023-08-08
JP7046872B2 (ja) 2022-04-04
CN105934240A (zh) 2016-09-07
US11944706B2 (en) 2024-04-02
DK3096741T3 (da) 2020-09-28
CN112870163A (zh) 2021-06-01
JP2022101548A (ja) 2022-07-06
ES2821758T3 (es) 2021-04-27
AU2015208837B2 (en) 2020-06-18
JP2019218349A (ja) 2019-12-26
KR20220061286A (ko) 2022-05-12
EP3791863B1 (en) 2025-09-10
JP2017502997A (ja) 2017-01-26
KR102541164B1 (ko) 2023-06-08
KR102396026B1 (ko) 2022-05-09
CN105934240B (zh) 2021-02-09
KR102507475B1 (ko) 2023-03-07
US10561610B2 (en) 2020-02-18
MX2021000174A (es) 2021-03-25
AU2022218603A1 (en) 2022-09-15
MX2016009529A (es) 2016-10-17
AU2020227129B2 (en) 2022-06-30
WO2015110957A3 (en) 2015-12-03
AU2020227129A1 (en) 2020-10-01
MX384911B (es) 2025-03-14
US20160354313A1 (en) 2016-12-08
US20200222324A1 (en) 2020-07-16
KR20230039752A (ko) 2023-03-21
CA2936514A1 (en) 2015-07-30
ZA201604831B (en) 2018-05-30
EP3096741B1 (en) 2020-09-02
EA201691448A1 (ru) 2016-12-30
KR20160110410A (ko) 2016-09-21
EA037503B1 (ru) 2021-04-05
AU2022218603B2 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
US11944706B2 (en) Hybridosomes, compositions comprising the same, processes for their production and uses thereof
Li et al. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape
CN106619515A (zh) 脂质体组合物及其用途
WO2011105520A1 (ja) 抗原または薬物送達複合体
Moitra et al. Cancer stem cell-targeted gene delivery mediated by aptamer-decorated ph-sensitive Nanoliposomes
EP3740196B1 (en) Nanosystems as selective vehicles for drugs
WO2014030601A1 (ja) アニオン性を有する新規ナノバブルポリ－リポ・プレックスの製造方法
US20160038597A9 (en) Carrier that targets fucosylated molecule-producing cells
BR112016016802B1 (pt) Processo para fabricar um carreador biocompatível híbrido (hibridossoma)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191001

R150 Certificate of patent or registration of utility model

Ref document number: 6598786

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250